Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Description of Toripalimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade

Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

The Structure, Activity, and Application of Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

The Antibody

Toripalimab Biosimilar is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. It is a biosimilar version of the original drug, Toripalimab, which was developed by Shanghai Junshi Biosciences Co., Ltd. The biosimilar version is produced by recombinant DNA technology and has the same amino acid sequence and structure as the original drug.

The Therapeutic Target

PD-1 is a protein that is found on the surface of immune cells called T-cells. It is a checkpoint receptor that plays a critical role in regulating the immune response. When PD-1 binds to its ligands, PD-L1 and PD-L2, it inhibits the activity of T-cells, preventing them from attacking healthy cells in the body. This mechanism is important in maintaining immune tolerance and preventing autoimmune diseases.

The Mechanism of Action

Toripalimab Biosimilar works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This prevents the inhibitory signal from being transmitted, allowing T-cells to become activated and attack cancer cells. By targeting the PD-1 pathway, Toripalimab Biosimilar can enhance the body’s immune response against cancer cells, leading to their destruction.

The Applications

Toripalimab Biosimilar is currently being studied for its potential in treating various types of cancer, including melanoma, non-small cell lung cancer, and nasopharyngeal carcinoma. It has also shown promising results in clinical trials for the treatment of Hodgkin’s lymphoma and gastric cancer. In addition, Toripalimab Biosimilar is being investigated as a potential therapy for other diseases such as rheumatoid arthritis and multiple sclerosis.

The Research Grade

Toripalimab Biosimilar is available in a research grade form for use in preclinical studies and research purposes. It is not intended for human use and is strictly for laboratory use only. The research grade version allows scientists to study the effects of Toripalimab Biosimilar on different types of cancer cells and to better understand its mechanism of action.

The Advantages of Toripalimab Biosimilar

Compared to the original drug, Toripalimab Biosimilar offers several advantages. First, it is a more affordable option, making it more accessible to patients. Second, being a biosimilar, it has undergone rigorous testing and has been shown to have similar efficacy and safety as the original drug. Lastly, Toripalimab Biosimilar has the potential to increase competition in the market, leading to lower drug prices and improved patient access to treatment.

In Conclusion

Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade is a promising therapy for the treatment of various types of cancer. Its mechanism of action in targeting the PD-1 pathway makes it a valuable addition to the arsenal of cancer treatments. As more research is conducted, Toripalimab Biosimilar has the potential to improve patient outcomes and revolutionize the field of immunotherapy.

Toripalimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Toripalimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1540) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450